Navigation Links
Tris Pharma Announces Availability of the MyKidz® Iron Product Line - the Best Tasting Iron Supplements
Date:3/29/2011

MONMOUTH JUNCTION, N.J., March 29, 2011 /PRNewswire/ -- Tris Pharma, Inc., a specialty pharmaceutical company, announced today the highly anticipated re-launch of the MyKidz® Iron product line.  Since the 2007 launch of MyKidz Iron, it has attracted a loyal following of pediatricians, pediatric nurses and mothers.  When the previous marketer decided to focus its product pipeline in a different direction, availability of MyKidz Iron™ became limited, but the need for a great tasting iron supplement remained.  Tris Pharma is stepping-in to provide continuity of care, broader distribution, and ensure that the nutritional needs of infants and toddlers do not go unanswered.

MyKidz Iron products are a line of iron supplements without the strong metallic taste common to other marketed iron supplements.  MyKidz Iron products are based on a patent-pending, taste-neutral formula where the bad-tasting iron is complexed in a polymeric matrix. The formula further contains a berry/banana fruit flavor that makes it a pleasant tasting supplement which helps to increase compliance.  Dr. Louis Reed, a Texas based Pediatrician who has always recommended these supplements, said, "I like MyKidz Iron products because they are the only iron supplements that don't taste like rusty nails, so kids will actually take them."  Additionally, these supplements contain no artificial dyes, alcohol or sugars and the special formula helps to reduce the staining of teeth associated with iron.  

Iron deficiency is a common problem among children, but it is frequently not detected, and it has long-term health implications for children.  It can lead to anemia and/or irreversible effects on children's cognitive and behavioral development.  Studies have shown that 4 percent of 6 month olds and 12 percent of 12 month olds tend to be iron deficient.  Children between the ages of 1-3 years of age have rates of iron deficiency between 6-15 percent.  Pre-term infants, infants who are exclusively breastfed and infants who are at risk for developmental disabilities seem to be at higher risk to develop iron deficiency (1).

"When we received overwhelming feedback," said Ketan Mehta, President and CEO of Tris Pharma, "we realized that there was still a need for a children's iron supplement that was not met by other alternatives.  By making these products available again we, at Tris Pharma, expect the MyKidz Iron product line will positively impact the above statistics."

Three formulations are currently available:

  • MyKidz Iron is an iron supplement with vitamins A, C & D, a 2ml dose delivers 10mg of elemental iron plus 1500 IU of Vitamin A, 35mg of Vitamin C and 400 IU of Vitamin D.
  • MyKidz Iron 10 is a high dose iron only, a 1.5 ml dose delivers 15mg of elemental iron.
  • MyKidz Iron FL is a prescription iron supplement with vitamins A, C & D, plus fluoride.  In addition to the 10mg of elemental iron and above stated vitamin concentrations, it contains .25mg of fluoride per dose for toddlers requiring fluoride supplementation.

Tris Pharma has launched a new website with detailed information about these iron supplements. For more information including full prescribing information, please visit www.mykidziron.com or call toll free (866)697-9283.

About Tris Pharma

Tris Pharma is a specialty pharmaceutical company focused on the research and development of drug delivery technology based products.  Through its OralXR+ platform, Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill.  Tris' research, development, and manufacturing facilities are located in Monmouth Junction, New Jersey, USA. For more information, visit www.trispharma.com.

MyKidz is a trademark of Tris Pharma, Inc.

REFERENCE:

1.  AAP News Release "AAP OFFERS GUIDANCE TO BOOST IRON LEVELS IN CHILDREN." Website. http://www.aap.org/pressroom/Ironfinal.pdf.  October 5, 2010.

© 2011 Tris Pharma, Inc.  Monmouth Junction, NJ.


'/>"/>
SOURCE Tris Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers ... an innovative way to use nonlinear optical imaging to ... new drugs. ... will show how researchers from BioPharmX and the Wellman ... used a suite of imaging techniques in what is ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):